Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer SubtypesSpencer S. Watson, James E. Korkola|Cell Systems|2018Cited by 100
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancerHayley Donnella, Sourav Bandyopadhyay, Rebecca S. Levin et al.|Nature Chemical Biology|2018Cited by 92
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant diseaseRebecca Smith, James E. Korkola|Scientific Reports|2020Cited by 74